{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:12:37Z","timestamp":1773231157987,"version":"3.50.1"},"reference-count":41,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20ek0109312h0003"],"award-info":[{"award-number":["20ek0109312h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,1,19]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Spondyloarthritis (SpA) is known as series of immune-mediated inflammatory disease of the axial and peripheral joints. Human leucocyte antigen (HLA)-B27 is a genetic risk factor for SpA. Recent evidence suggests that the interleukin \u221217 (IL17) axis strongly contributes to SpA. This study aimed to assess the efficacy of an IL17A peptide-based vaccine on SpA manifestations in model rats.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>HLA-B27\/human \u03b2<jats:sub>2<\/jats:sub>-microglobulin (h\u03b2<jats:sub>2<\/jats:sub>M) transgenic rats were immunised with heat-inactivated <jats:italic>Mycobacterium tuberculosis<\/jats:italic> (MT) to develop spondylitis and arthritis as an experimental SpA model after immunisation with a keyhole limpet hemocyanin-conjugated IL17A peptide-based vaccine with an alum adjuvant three times. The IL17A antibody titre was assessed using ELISA, and arthritis score and joint thickness were monitored two times a week. Enzyme-linked immunospot (ELISpot) assays for IL4- and interferon-\u03b3-secreting splenocytes were conducted to evaluate IL17A-specific T cell activation. We also evaluated the effect of IL17A vaccine in SpA therapeutic model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The IL17A peptide-based vaccine with alum adjuvant successfully induced antibody production and suppressed the arthritis score and joint thickness. X-ray and histological analyses showed that enthesitis, bone destruction and new bone formation were inhibited by the IL17A vaccine. The ELISpot assay showed that the IL17A peptide-based vaccine did not elicit any IL17A-reactive T cell responses. IL17A vaccine tends to mitigate, but not significant, in SpA treatment model. These data showed that the peptide-based vaccine targeting IL17A alleviated the SpA phenotype in a heat-inactivated MT-induced SpA model in HLA-B27\/h\u03b2<jats:sub>2<\/jats:sub>M transgenic rats.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>IL17A peptide-based vaccine may be a therapeutic option for SpA treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002851","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T09:47:36Z","timestamp":1675417656000},"page":"e002851","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Peptide-based vaccine targeting IL17A attenuates experimental spondyloarthritis in HLA-B27 transgenic rats"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5722-3764","authenticated-orcid":false,"given":"Hiroki","family":"Hayashi","sequence":"first","affiliation":[{"name":"Department of Health Development and Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Health Development and Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Yanagida","sequence":"additional","affiliation":[{"name":"Department of Health Development and Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Health Development and Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"},{"name":"Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Health Development and Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"},{"name":"Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Tenma","sequence":"additional","affiliation":[{"name":"FunPep.Co, Suita, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Toyoura","sequence":"additional","affiliation":[{"name":"FunPep.Co, Suita, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sotaro","family":"Kawabata","sequence":"additional","affiliation":[{"name":"FunPep.Co, Suita, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Ehara","sequence":"additional","affiliation":[{"name":"FunPep.Co, Suita, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Asaki","sequence":"additional","affiliation":[{"name":"FunPep.Co, Suita, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Sakaguchi","sequence":"additional","affiliation":[{"name":"FunPep.Co, Suita, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Tomioka","sequence":"additional","affiliation":[{"name":"FunPep.Co, Suita, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munehisa","family":"Shimamura","sequence":"additional","affiliation":[{"name":"Department of Health Development and Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"},{"name":"Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Rakugi","sequence":"additional","affiliation":[{"name":"Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Tomita","sequence":"additional","affiliation":[{"name":"Graduate School of Health Science, Morinomiya University of Medical Sciences, Osaka, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Nakagami","sequence":"additional","affiliation":[{"name":"Department of Health Development and Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"key":"2025090312142715000_9.1.e002851.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406182"},{"key":"2025090312142715000_9.1.e002851.2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.rdc.2020.01.002","article-title":"What does human leukocyte antigen B27 have to do with spondyloarthritis?","volume":"46","author":"Fahed","year":"2020","journal-title":"Rheum Dis Clin North Am"},{"key":"2025090312142715000_9.1.e002851.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-002-0237-4"},{"key":"2025090312142715000_9.1.e002851.4","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2667"},{"key":"2025090312142715000_9.1.e002851.5","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/acr.21688","article-title":"Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?","volume":"64","author":"Kiltz","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312142715000_9.1.e002851.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.24483"},{"key":"2025090312142715000_9.1.e002851.7","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/1756-185X.13487","article-title":"Hla-B27 prevalence in axial spondyloarthritis patients and in blood donors in a Lebanese population: results from a nationwide study","volume":"22","author":"Ziade","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2025090312142715000_9.1.e002851.8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12891-017-1639-5","article-title":"Hla B27 antigen in middle Eastern and Arab countries: systematic review of the strength of association with axial spondyloarthritis and methodological gaps","volume":"18","author":"Ziade","year":"2017","journal-title":"BMC Musculoskelet Disord"},{"key":"2025090312142715000_9.1.e002851.9","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1002\/art.34480","article-title":"Autoimmune epididymoorchitis is essential to the pathogenesis of male-specific spondylarthritis in HLA-B27-transgenic rats","volume":"64","author":"Taurog","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025090312142715000_9.1.e002851.10","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3389\/fimmu.2017.00920","article-title":"Innate immune activation can trigger experimental spondyloarthritis in HLA-B27\/hu\u03b22m transgenic rats","volume":"8","author":"van Tok","year":"2017","journal-title":"Front Immunol"},{"key":"2025090312142715000_9.1.e002851.11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19020530","article-title":"Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints","volume":"19","author":"Boutet","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2025090312142715000_9.1.e002851.12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41584-018-0091-8","article-title":"Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis","volume":"14","author":"Gravallese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2025090312142715000_9.1.e002851.13","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.56"},{"key":"2025090312142715000_9.1.e002851.14","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025090312142715000_9.1.e002851.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61134-4"},{"key":"2025090312142715000_9.1.e002851.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"2025090312142715000_9.1.e002851.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"2025090312142715000_9.1.e002851.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"2025090312142715000_9.1.e002851.19","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2017.46","article-title":"Special issue on therapeutic antibodies and biopharmaceuticals","volume":"49","author":"Chung","year":"2017","journal-title":"Exp Mol Med"},{"key":"2025090312142715000_9.1.e002851.20","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1161\/HYPERTENSIONAHA.118.11084","article-title":"Recent advances in therapeutic vaccines to treat hypertension","volume":"72","author":"Nakagami","year":"2018","journal-title":"Hypertension"},{"key":"2025090312142715000_9.1.e002851.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191895","article-title":"Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin\/kexin type 9 (PCSK9) epitope in mice","volume":"13","author":"Kawakami","year":"2018","journal-title":"PLoS One"},{"key":"2025090312142715000_9.1.e002851.22","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/HYPERTENSIONAHA.118.11316","article-title":"Therapeutic vaccine against S100A9 (S100 calcium-binding protein A9) inhibits thrombosis without increasing the risk of bleeding in ischemic stroke in mice","volume":"72","author":"Kawano","year":"2018","journal-title":"Hypertension"},{"key":"2025090312142715000_9.1.e002851.23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060493","article-title":"Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice","volume":"8","author":"Nakagami","year":"2013","journal-title":"PLoS One"},{"key":"2025090312142715000_9.1.e002851.24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1322009111"},{"key":"2025090312142715000_9.1.e002851.25","doi-asserted-by":"crossref","first-page":"43920","DOI":"10.1038\/srep43920","article-title":"A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction","volume":"7","author":"Watanabe","year":"2017","journal-title":"Sci Rep"},{"key":"2025090312142715000_9.1.e002851.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.11227"},{"key":"2025090312142715000_9.1.e002851.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.01.006"},{"key":"2025090312142715000_9.1.e002851.28","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/art.40770","article-title":"Interleukin-17A inhibition diminishes inflammation and new bone formation in experimental spondyloarthritis","volume":"71","author":"van Tok","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090312142715000_9.1.e002851.29","doi-asserted-by":"publisher","DOI":"10.2217\/imt.12.129"},{"key":"2025090312142715000_9.1.e002851.30","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8010083","article-title":"Development of an IL-17A DNA vaccine to treat systemic lupus erythematosus in mice","volume":"8","author":"Koriyama","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"2025090312142715000_9.1.e002851.31","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3389\/fimmu.2020.01855","article-title":"Multifactorial design of a supramolecular peptide anti-IL-17 vaccine toward the treatment of psoriasis","volume":"11","author":"Shores","year":"2020","journal-title":"Front Immunol"},{"key":"2025090312142715000_9.1.e002851.32","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200636662"},{"key":"2025090312142715000_9.1.e002851.33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217927"},{"key":"2025090312142715000_9.1.e002851.34","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"2025090312142715000_9.1.e002851.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2003.09.013"},{"key":"2025090312142715000_9.1.e002851.36","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.298"},{"key":"2025090312142715000_9.1.e002851.37","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1253\/circj.CJ-20-0703","article-title":"Future directions of therapeutic vaccines for chronic diseases","volume":"84","author":"Nakamaru","year":"2020","journal-title":"Circ J"},{"key":"2025090312142715000_9.1.e002851.38","doi-asserted-by":"crossref","first-page":"622770","DOI":"10.3389\/fimmu.2021.622770","article-title":"Clinical trials supporting the role of the IL-17\/IL-23 axis in axial spondyloarthritis","volume":"12","author":"Ceribelli","year":"2021","journal-title":"Front Immunol"},{"key":"2025090312142715000_9.1.e002851.39","first-page":"27","article-title":"Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults","volume":"38","author":"Erdes","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312142715000_9.1.e002851.40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31946-9"},{"key":"2025090312142715000_9.1.e002851.41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01550"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:14:34Z","timestamp":1756926874000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,2,3]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/rmdopen-2022-002851"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002851","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}